The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Eleven Biotherapeutics, Inc. COM 286221106 469 1,466,417 SH   SOLE 1 1,466,417 0 0
Seres Therapeutics Inc. COM 81750R102 374,060 14,083,579 SH   SOLE 1 14,083,579 0 0
T2 Biosystems, Inc. COM 89853L104 7,314 741,755 SH   SOLE 1 741,755 0 0